APPLICATION FOR

UNITED STATES PATENT

BY

THOMAS J. F. NIELAND

MONTY KRIEGER

AND

TOMAS KIRCHAUSEN

FOR

COMPOUNDS FOR MODULATION OF CHOLESTEROL TRANSPORT

COMPOUNDS FOR MODULATION OF CHOLESTEROL TRANSPORT

Cross Reference to Related Applications

This application claims priority to U.S. Provisional Application Serial No. 60/417,083 filed on October 8, 2002.

Field of the Invention

The present invention is generally in the area of compounds for modulation of cholesterol transport and lipid regulation mediated *via* the SR-BI scavenger receptor.

Background of the Invention

The intercellular transport of lipids through the circulatory system requires the packaging of these hydrophobic molecules into water-soluble carriers, called lipoproteins, and the regulated targeting of these lipoproteins to appropriate tissues by receptor-mediated pathways. The most well characterized lipoprotein receptor is the

5   LDL receptor, which binds to apolipoproteins B-100 (apoB-100), and E (apoE), which are constituents of low density lipoprotein (LDL), the principal cholesteryl-ester transporter in human plasma, very low-density lipoprotein (VLDL), a triglyceride-rich carrier synthesized by the liver, intermediate-density lipoprotein (IDL), and catabolized chylomicrons (dietary triglyceride-rich carriers).

10   Kreiger, et al., in WO96/00288 *"Class BI and CI Scavenger Receptors"* by Massachusetts Institute of Technology, U.S. Patent Nos. 6,359,859 and 6,429,289 ("Krieger, et al.") characterized and cloned hamster and murine homologs of SR-BI, an AcLDL and LDL binding scavenger receptor. It was reported by Kreiger, et al. that the SR-BI receptor is expressed principally in steroidogenic tissues and liver and appears to

15   mediate HDL-transfer and uptake of cholesterol. Competitive binding studies show that SR-BI binds LDL, modified LDL, negatively charged phospholipid, and HDL. Direct binding studies show that SR-BI expressed in mammalian cells (for example, a variant of CHO cells) binds HDL, without cellular degradation of the HDL-apoprotein, and lipid is accumulated within cells expressing the receptor. These studies indicated that SR-BI

20   might play a major role in transfer of cholesterol from peripheral tissues, *via* HDL, into

1

the liver and steroidogenic tissues, and that increased or decreased expression in the liver or other tissues may be useful in regulating uptake of cholesterol by cells expressing SR-BI, thereby decreasing levels in foam cells and deposition at sites involved in atherogenesis.

5   Subsequent studies confirmed that SR-BI not only binds to lipid, but also transfers cholesterol into and out of cells, as described in U.S. Patent Nos. 5,962,322 and 5,925,333 to Krieger, et al. Moreover, SR-BI is preferentially expressed in steroidogenic tissues, and plays a role in lipid regulation, affecting not only cholesterol levels but also female fertility, as described by WO99/11288 by Massachusetts Institute of Technology.

10   The role of SR-BI in cholesterol uptake and transfer can be manipulated via SR-BI, for example, as demonstrated using probucol treatment to restore female fertility, as described by Miettinen, et al. (2001) *J. Clin. Invest.* 108(11):1717-1722. This work clearly demonstrates that there is a need for additional drugs that that stimulate or inhibit SR-BI mediated lipid uptake and metabolism.

15   It is an object of the present invention to provide drugs and methods and reagents for designing drugs, that can stimulate or inhibit the binding to and lipid movements mediated by SR-BI and redirect uptake and metabolism of lipids and cholesterol by cells.

Summary of the Invention

Compounds for regulation of cholesterol transport are described which are based
20 on regulation of the expression or function of SR-BI. SR-BI mediates both selective uptake of lipids, mainly cholesterol esters, from HDL to cells and efflux of cholesterol from cells to lipoproteins. The mechanism underlying these lipid transfers is distinct from classic receptor mediated endocytosis, but remains poorly understood. To investigate SR-BI's mechanism of action and *in vivo* function, a high throughput screen
25 was developed to identify small molecule inhibitors of SR-BI-mediated lipid transfer in intact cells. Two hundred compounds were identified that block lipid transport (BLTs), both selective uptake and efflux, in the low nanomolar to micromolar range. The effects of these compounds were highly specific to the SR-BI pathway, because they did not interfere with clathrin-based receptor-mediated endocytosis or with other forms of
30 intracellular vesicular traffic. As demonstrated by the examples, five BLTs (BLT-1 [MIT 9952-53]; BLT-2 [MIT 9952-61]; BLT-3 [MIT 9952-19]; BLT-4 [MIT 9952-29]; and

2

BLT-5 [MIT 9952-6]) enhanced, rather than inhibited, HDL binding by increasing SR-BI's binding affinity for HDL (decreased dissociation rates). Others inhibited HDL binding. These should be useful in the management of atherosclerosis, treatment of infertility, or conversely, as contraceptives and in the treatment of Tangier's disease.

Brief Description of the Drawings

Figures 1A-1C are graphs of the concentration dependence of the inhibition by BLTs of SR-BI-mediated lipid transfer between HDL and cells. ldlA[mSR-BI] cells were incubated with the indicated concentrations of BLTs and their effects on (A) DiI uptake from DiI-HDL, (B) [^{3}H]CE uptake from [^{3}H]CE-HDL and (C) the efflux of [^{3}H]cholesterol from cells to HDL were determined. The 100 % of control values were: A, 50.6 ng HDL protein equivalents/well (384-well plates) and B, 3908 ng HDL protein equivalents/mg cellular protein. In C, the data were normalized such that the maximum amount of [^{3}H]cholesterol transferred from cells to HDL in the absence of compounds (55.7% of total) was set to 100%. The 0% value corresponds to the efflux of [^{3}H] cholesterol transferred from ldlA[mSR-BI] cells to HDL without BLTs and in the presence of saturating inhibitory amounts of the specific anti-SR-BI blocking monoclonal antibody KKB-1 (15% of total). The efflux of [^{3}H]cholesterol from ldlA-7 cells measured in the absence or presence of KKBI was 15% and 10% of total cellular [^{3}H]cholesterol, respectively.

Figures 2A-2D are graphs of cell surface expression of SR-BI. ldlA[mSR-BI] and ldlA-7 cells were treated for 3 hrs with or without BLTs at their corresponding IC$_{CE}$95 concentrations (1 μM for BLT-1 (MIT 9952-53) and BLT-2 (MIT 9952-61), 50 μM for BLT-3 (MIT 9952-19), BLT-4 (MIT 9952-29) and BLT-5 (MIT 9952-6)) followed by determination of surface expression levels of SR-BI by flow cytometry. Panels A-C show histograms of the surface expression for ldlA[mSR-BI] cells without BLTs, ldlA[mSR-BI] cells with 1 μM BLT-1 (MIT 9952-53), and ldlA-7 cells without BLTs, respectively. Panel D summarizes the results in ldlA[mSR-BI] cells for all five BLTs, with the value determined without compounds set to 100%. n, number of independent determinations; SD, standard deviation.

Figures 3A-3E shows the effects of BLTs on SR-BI-mediated cholesterol ether uptake from HDL, cellular cholesterol efflux to HDL and HDL binding. The effects of

3

indicated concentrations of BLTs (panels A-E) on SR-BI-mediated uptake of [^{3}H]CE from [^{3}H]CE-HDL (solid lines, no symbols), efflux of [^{3}H]cholesterol from cells to HDL (dashed lines), or binding of ^{125}I-HDL to cells (solid lines, filled symbols) were determined using ldlA[mSR-BI] cells. To simplify comparisons, the lowest observed

5   [^{3}H]CE uptake and [^{3}H]cholesterol efflux values (from Figure 2) were compared as 0% and the values in the absence of BLTs as 100%. The 100% control value for the ^{125}I-HDL binding in the absence of BLTs was 403 ng HDL protein/mg cell protein.

Figure 4 is a graph of the effects of BLT-1 (MIT 9952-53) on the concentration dependence of ^{125}I-HDL binding to ldlA[mSR-BI] cells. The binding of ^{125}I-HDL to

10   ldlA[mSR-BI] cells was determined in duplicate at the indicated concentrations of HDL in the presence (blue) or absence (black) of 1 μM BLT-1 (MIT 9952-53; IC$_{CE}$95). Each value was corrected for binding of ^{125}I-HDL in the presence of 40-fold excess of unlabeled HDL to ldlA [mSR-BI] cells in the presence of BLT-1 (MIT 9952-53).

Detailed Description of the Invention

15   **I.   Modulators of SR-BI transport of cholesterol.**

Libraries of compounds have been screened using an assay such as the assays described below for alteration in HDL binding. These compounds can be proteins, DNA sequences, polysaccharides, or synthetic organic compounds. Approximately 200 that have been identified as having activity are listed below in Table I.

20   **II.   Screening of compounds to inhibit or enhance SR-BI activity.**

The SR-BI proteins and antibodies and their DNAs can be used in screening of drugs which modulate the activity and/or the expression of SR-BI. The cDNA encoding SR-BI has been cloned and is reported U.S. Patent No. 6,359,859 and 6,429,289 and is listed in GenBank. The cDNA encoding SR-BI yields a predicted protein sequence of

25   509 amino acids. The drugs which enhance SR-BI activity should be useful in treating or preventing atherosclerosis, fat uptake by adipocytes, and some types of endocrine disorders. The drugs which inhibit SR-BI activity should be useful as contraceptives and in the treatment of Tangiers disease.

The assays described below clearly provide routine methodology by which a

30   compound can be tested for an inhibitory effect on binding of a specific compound, such as a radiolabeled modified HDL and LDL or polyion. The *in vitro* studies of compounds

which appear to inhibit binding selectively to the receptors can then be confirmed by animal testing. Since the molecules are so highly evolutionarily conserved, it is possible to conduct studies in laboratory animals such as mice to predict the effects in humans.

Studies based on inhibition of binding are predictive for indirect effects of
5   alteration of receptor binding. For example, inhibition of cholesterol-HDL binding to the SR-BI receptor leads to decreased uptake by cells of cholesterol and therefore inhibits cholesterol transport by cells expressing the SR-BI receptor. Increasing cholesterol-HDL binding to cells increases removal of lipids from the blood stream and thereby decreases lipid deposition within the blood stream. Studies have been conducted using a stimulator
10 to enhance macrophage uptake of cholesterol and thereby treat atherogenesis, using M-CSF (Schaub, et al., 1994 *Arterioscler. Thromb.* 14(1), 70-76; Inaba, et al., 1993 *J. Clin. Invest.* 92(2), 750-757).

The following assays can be used to screen for compounds which are effective in methods for alter SR-BI expression, concentration, or transport of cholesterol.
15   ***Assays for Alterations in SR-BI binding or expression***

Northern blot analysis of murine tissues shows that SR-BI is most abundantly expressed in adrenal, ovary, liver, testes, and fat and is present at lower levels in some other tissues. SR-BI mRNA expression is induced upon differentiation of 3T3-L1 cells into adipocytes. Both SR-BI and CD36 display high affinity binding for acetylated LDL
20 with an apparent dissociation constant in the range of approximately 5 μg protein/ml. The ligand binding specificities of CD36 and SR-BI, determined by competition assays, are similar, but not identical: both bind modified proteins (acetylated LDL, maleylated BSA), but not the broad array of other polyanions (e.g. fucoidin, polyinosinic acid, polyguanosinic acid) which are ligands of the class A receptors. SR-BI displays high
25 affinity and saturable binding of HDL which is not accompanied by cellular degradation of the HDL. HDL inhibits binding of AcLDL to CD36, suggesting that it binds HDL, similarly to SR-BI. Native LDL, which does not compete for the binding of acetylated LDL to either class A receptors or CD36, competes for binding to SR-BI.

125I-AcLDL Binding, Uptake and Degradation Assays.
30   Scavenger receptor activities at 37°C are measured by ligand binding, uptake and degradation assays as described by Krieger, *Cell* 33, 413-422, 1983; and Freeman et al.,

5

(1991) *Proc Natl Acad Sci USA*. 1991 Jun 1;88(11):4931-5). The values for binding and uptake are combined and are presented as binding plus uptake observed after a 5 hour incubation and are expressed as ng of ^{125}I-AcLDL protein per 5 hr per mg cell protein. Degradation activity is expressed as ng of ^{125}I-AcLDL protein degraded in 5 hours per

5 mg of cell protein. The specific, high affinity values represent the differences between the results obtained in the presence (single determinations) and absence (duplicate determinations) of excess unlabeled competing ligand. Cell surface 4°C binding is assayed using either method A or method B as indicated. In method A, cells are prechilled on ice for 15 min, re-fed with ^{125}I-AcLDL in ice-cold medium B supplemented

10 with 10% (v/v) fetal bovine serum, with or without 75 - 200 µg/ml unlabeled M-BSA, and incubated 2 hr at 4°C on a shaker. Cells are then washed rapidly three times with Tris wash buffer (50 mM Tris-HCl, 0.15 M NaCl, pH 7.4) containing 2 mg/ml BSA, followed by two 5 min washes, and two rapid washes with Tris wash buffer without BSA. The cells are solubilized in 1 ml of 0.1 N NaOH for 20 min at room temperature

15 on a shaker, 30 µl are removed for protein determination, and the radioactivity in the remainder is determined using a LKB gamma counter. Method B differs from method A in that the cells are prechilled for 45 minutes, the medium contains 10 mM HEPES and 5% (v/v) human lipoprotein-deficient serum rather than fetal bovine serum, and the cell-associated radioactivity released by treatment with dextran sulfate is measured as

20 described by Krieger, (1983) *Cell* 33, 413-422; Freeman et al., (1991) *Proc Natl Acad Sci USA*. 1991 Jun 1;88(11):4931-5)).

Northern blot analysis.

0.5 micrograms of poly(A)+ RNA prepared from different murine tissues or from 3T3-L1 cells on zero, two, four, six or eight days after initiation of differentiation into

25 adipocytes as described by Baldini et al., 1992 *Proc. Natl. Acad. Sci. U.S.A.* 89, 5049-5052, is fractionated on a formaldehyde/agarose gel (1.0%) and then blotted and fixed onto a Biotrans™ nylon membrane. The blots are hybridized with probes that are ^{32}P-labeled (2 x 10^6 dpm/ml, random-primed labeling system). The hybridization and washing conditions, at 42°C and 50°C, respectively, are performed as described by

30 Charron et al., 1989 *Proc. Natl. Acad. Sci. U.S.A.* 86, 2535-2539. The probe for SR-BI mRNA analysis was a 0.6 kb BamHI fragment from the cDNAs coding region. The

coding region of murine cytosolic hsp70 gene (Hunt and Calderwood, 1990 *Gene* 87, 199-204) is used as a control probe for equal mRNA loading.

SR-BI protein in tissues is detected by blotting with polyclonal antibodies to SR-BI.

5   *HDL Binding Studies*

HDL and VLDL binding to SR-BI and CD36 are conducted as described for LDL and modified LDL.

Studies conducted to determine if the HDL which is bound to SR-BI is degraded or recycled and if lipid which is bound to the HDL is transferred into the cells are

10   conducted using fluorescent lipid-labeled HDL, ^{3}H-cholesteryl ester labeled HDL and ^{125}I-HDL added to cultures of transfected or untransfected cells at a single concentration (10 µg protein/ml). HDL associated with the cells is measured over time. A steady state is reached in approximately thirty minutes to one hour. A fluorescent ligand, DiI, or ^{3}H-cholesterol ester is used as a marker for lipid (for example, cholesterol or cholesterol

15   ester) uptake by the cell. Increasing concentration of DiI indicates that lipid is being transferred from the HDL to the receptor, then being internalized by the cell. The DiI-depleted HDL is then released and replaced by another HDL molecule.

HDL Binding to SR-BI

Competition binding studies demonstrate that HDL and VLDL (400 µg/ml)

20   competitively inhibit binding of ^{125}I-AcLDL to SR-BI. Direct binding of ^{125}I-HDL to cells expressing SR-BI is also determined.

Tissue distribution of SR-BI

To explore the physiological functions of SR-BI, the tissue distribution of SR-BI was determined in murine tissues, both in control animals and estrogen treated animals,

25   as described in the following examples. Each lane is loaded with 0.5 µg of poly(A)+ RNA prepared from various murine tissues: kidney, liver, adrenals, ovaries, brain, testis, fat, diaphragm, heart, lung, spleen, or other tissue. The blots are hybridized with a 750 base pair fragment of the coding region of SR-BI. SR-BI mRNA is most highly expressed in adrenals, ovary and liver is moderately or highly expressed in fat depended

30   on the source and is expressed at lower levels in other tissues. Blots using polyclonal antibodies to a cytoplasmic region of SR-BI demonstrate that very high levels of protein

7

are present in liver, adrenal tissues, and ovary in mice and rats, but only very low or undetectable levels are present in either white or brown fat, muscle or a variety of other tissues. Bands in the rat tissues were present at approximately 82 kD. In the mouse tissues, the 82 kD form observed in the liver and steroidogenic tissues is the same size

5   observed in SR-BI-transfected cultured cells.

Assays for testing compounds for useful activity can be based solely on interaction with the receptor protein, preferably expressed on the surface of transfected cells such as those described above, although proteins in solution or immobilized on inert substrates can also be utilized, where the indication is inhibition or increase in binding of

10   lipoproteins.

Alternatively, the assays can be based on interaction with the gene sequence encoding the receptor protein, preferably the regulatory sequences directing expression of the receptor protein. For example, antisense which binds to the regulatory sequences, and/or to the protein encoding sequences can be synthesized using standard

15   oligonucleotide synthetic chemistry. The antisense can be stabilized for pharmaceutical use using standard methodology (encapsulation in a liposome or microsphere; introduction of modified nucleotides that are resistant to degradation or groups which increase resistance to endonucleases, such as phosphorothiodates and methylation), then screened initially for alteration of receptor activity in transfected or naturally occurring

20   cells which express the receptor, then *in vivo* in laboratory animals. Typically, the antisense would inhibit expression. However, sequences which block those sequences which "turn off" synthesis can also be targeted.

II.   Methods of Regulation of SR-BI cholesterol transport.

The HDL receptor SR-BI plays an important role in controlling the structure and

25   metabolism of HDL (Acton, et al.. (1996) *Science* **271**, 518-20; Krieger, M. (1999) *Annu Rev Biochem* **68**, 523-58). Studies in mice have shown that alterations in SR-BI expression can profoundly influence several physiologic systems, including those involved in biliary cholesterol secretion, female fertility, red blood cell development, atherosclerosis and the development of coronary heart disease (Trigatti, et al. (1999) *Pro.*

30   *Nat. Acad. Sci. USA* **96**, 9322-7; Kozarsky, et al. (2000) *Arterio. Thromb. Vasc. Biol.* **20**, 721-7; Arai, et al. (1999) *J. Biol. Chem.* **274**, 2366-71; Holm, et al. (2002) *Blood* **99**,

8

1817-24; Miettinen, et al.(2001) *J. Clin. Invest.* **108**, 1717-22; Ueda, et al. (2000) *J. Biol. Chem.* **275**, 20368-73; Kozarsky, et al. (1997) *Nature* **387**, 414-7; Braun, et al. (2002) *Cir.Res.* **90**, 270-276; Mardones, et al. (2001) *J. Lipid Res.* **42**, 170-180)) SR-BI controls HDL metabolism by mediating the cellular selective uptake of cholesteryl esters and

5   other lipids from plasma HDL. During selective uptake (Glass, et al. (1983) *Proc. Nat. Acad. Sci. USA* **80**, 5435-9; Glass, et al. (1985) *J. Biol. Chem.* **260**, 744-50; Stein, et al. (1983) *Biochimica et Biophysica Acta* **752**, 98-105), HDL binds to SR-BI and its lipids, primarily neutral lipids such as cholesteryl esters in the core of the particles, are transferred to the cells. The lipid-depleted particles are subsequently released back into

10   the extracellular space. Although the mechanism of SR-BI-mediated selective lipid uptake and the subsequent intracellular transport of these lipids has only just begun to be explored (Krieger 1999; Krieger, M. (2001) *J Clin Invest* **108**, 793-7; Uittenbogaard, et al. (2002) J. *Biol. Chem.* **277**, 4925-4931), it is clearly fundamentally different from the pathway of receptor-mediated endocytosis via clathrin-coated pits and vesicles used by

15   the low-density lipoprotein (LDL) receptor to deliver cholesterol esters from LDL to cells (Brown, M. S. & Goldstein, J. L. (1986) *Science* **232**, 34-47). SR-BI can also mediate cholesterol efflux from cells to HDL (Temel, et al. (2002) *J Biol Chem* **8**, 8).

It has now been demonstrated that SR-BI plays critical roles in HDL lipid metabolism and cholesterol transport. SR-BI appears to be responsible for cholesterol

20   delivery to steroidogenic tissues and liver, and actually transfers cholesterol from HDL particles through the liver cells and into the bile canniculi, where it is passed out into the intestine. Data indicates that SR-BI is also expressed in the intestinal mucosa. It would be useful to increase expression of SR-BI in cells in which uptake of cholesterol can be increased, freeing HDL to serve as a means for removal of cholesterol from storage cells

25   such as foam cells where it can play a role in atherogenesis.

Compounds which alter receptor protein binding are preferably administered in a pharmaceutically acceptable vehicle. Suitable pharmaceutical vehicles are known to those skilled in the art. For parenteral administration, the compound will usually be dissolved or suspended in sterile water, phosphate buffered saline, or saline. For enteral

30   administration, the compound will be incorporated into an inert carrier in tablet, liquid, or capsular form. Suitable carriers may be starches or sugars and include lubricants,

flavorings, binders, and other materials of the same nature. The compounds can also be administered locally by topical application of a solution, cream, gel, or polymeric material (for example, a Pluronic™, BASF). The compounds may also be formulated for sustained or delayed release.

5 Alternatively, the compound may be administered in liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a patient are known to those skilled in the art. U.S. Patent No. 4,789,734 describe methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate

10 phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A review of known methods is by G. Gregoriadis, Chapter 14. "Liposomes", *Drug Carriers in Biology and Medicine* pp. 287-341 (Academic Press, 1979). Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract

15 directly into the bloodstream. Alternatively, the compound can be incorporated and the microspheres, or composite of microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patent No. 4,906,474, 4,925,673, and 3,625,214.

The present invention will be further understood by reference to the following

20 non-limiting examples.

Example 1: Identification of Chemical Inhibitors of the Selective Transfer of Lipids mediated by the HDL Receptor SR-BI.

Abbreviations

HDL	High Density Lipoprotein
mSR-BI	Murine Scavenger Receptor, class B, type I
LDL	Low Density Lipoprotein
BLT	Block Lipid Transfer
DiI	1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate
CE	Cholesteryl ether
DMSO	Dimethylsulfoxide
PBS	Phosphate Buffered Saline

EGF	Epidermal Growth Factor
VSV-G	Vesicular Stomatitis Virus Glycoprotein
EGFP	enhanced Green Fluorescent Protein
IC	Inhibitory Concentration
EC	Effective Concentration
ACTH	Adrenocorticotropic Hormone
FC	Free cholesterol

A high-throughput screen of a chemical library to identify potent small molecule inhibitors of SR-BI-mediated lipid transport. Five chemicals that block lipid transport, BLT-1-BLT-5 (BLT-1 corresponds to MIT 9952-53; BLT-2 corresponds to MIT 9952-61; BLT-3 corresponds to MIT 9952-19; BLT-4 corresponds to MIT 9952-29; and BLT-5 corresponds to MIT 9952-6), were tested and their effects on SR-BI activity in cultured cells. All five inhibited SR-BI-mediated selective lipid uptake from HDL and efflux of cellular cholesterol to HDL. One of these, BLT-1, was particularly potent, inhibiting lipid transport in the low nanomolar concentration range. Unexpectedly, all five BLTs enhanced HDL binding to SR-BI by increasing the binding affinity.

METHODS

Lipoproteins and Cells

Human HDL was isolated and labeled with either ^{125}I (^{125}I-HDL), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI, Molecular Probes; DiI-HDL) or [^3H]cholesteryl oleyl ether ([^3H]CE, [^3H]CE-HDL) (Gu, et al. (1998) *J. Biol. Chem.* 273, 26338-48; Gu, et al. (2000) *J. Biol. Chem.* 275, 29993-30001; Acton, et al. (1994) *J. Biol. Chem.* 269, 21003-9; Pitas, et al. (1981) *Arteriosclerosis* 1, 177-85). LDL receptor deficient Chinese hamster ovary cells that express low levels of endogenous SR-BI, ldlA-7 (Kingsley, et al. (1984) *Proc. Nat. Acad. Sci. USA* 81, 5454-8), ldlA-7 cells stably transfected to express high levels of murine SR-BI (ldlA[mSR-BI])(Acton, et al., 1996), Y1-BS1 murine adrenocortical cells that express high levels of SR-BI after induction with ACTH (Rigotti, et al. (1996) *J. Biol. Chem.* 271, 33545-9), monkey kidney BS-C1 cells (Kapoor, et al. (2000) *Journal of Cell Biology* 150, 975-88) and HeLa cells (Temel, et al. (2002) *J Biol Chem* 8, 8) were maintained as previously described.

High throughput screen

On day 0, ldlA[mSR-BI] cells were plated at 15,000 cells/well in clear bottom, black wall 384-well black assay plates (Costar) in 50 μl of medium A (Ham's F12 supplemented with 2 mM L-glutamine, 50 units/ml penicillin/50 μg/ml streptomycin, and 0.25 mg/ml G418.) supplemented with 10% fetal bovine serum (medium B). On day 1, cells were washed once with medium C (medium A with 1% (w/v) bovine serum albumin (BSA) and 25 mM HEPES pH 7.4, but no G418) and refed with 40 μl of medium C. Compounds (16,320 from the DiverSet E, Chembridge Corp.) dissolved in 100% DMSO were individually robotically 'pin' transferred (40 nl) (http://iccb.med.harvard.edu) to the wells to give a nominal concentration of 10 μM (0.01% DMSO). After an 1 hr incubation at 37°C, DiI- HDL (final concentration of 10 μg protein/ml) in 20 μl of medium C was added. Two hours later, fluorescence was measured at room temperature (approximately 2 minutes/plate) using a Analyst plate reader (Rhodamine B dichroic filter, emission 525 nm and excitation 580 nm; LJL Biosystems), both prior to removing the incubation medium (to test for autofluorescence and quenching) and after the medium removal and four washes with 80 μl of PBS/ 1mM $MgCl_2$/0.1 mM $CaCl_2$ to determine cellular uptake of DiI. All compounds were sampled in duplicate on different plates, and

each screen included ldlA-7 and ldlA[mSR-BI] cells in the presence and/or absence of a 40-fold excess of unlabeled HDL, but with no added compounds, as controls.

Assays

For the assays, all media and buffers contained 0.5 % DMSO and 0.5 % bovine
5   serum albumin to maintain compound solubility. Cells were pre-incubated with BLTs for 1 hr (or 2.5 hrs for transferrin, EGF and cholera toxin uptake experiments) and all the experiments were performed at 37°C. Detailed characterization of the BLTs and their effects was performed with compounds whose identities and purities were confirmed by LC-MS.

10   **(i) Lipid uptake from HDL, cholesterol efflux to HDL and HDL binding assays.**

Assays for the uptake of lipids from DiI-HDL and [^{3}H]CE-HDL, efflux of [^{3}H]cholesterol from labeled cells, and ^{125}I-HDL binding were performed as described by Acton et al. *Science* (1996) Jan 26;271(5248):518-20; Gu, et al. *J Biol Chem.* (2000) Sep 29;275(39):29993-30001; and Ji, et al., *J. Biol. Chem.* (1997) **272,** 20982-5. In some
15   experiments, values were normalized so that the 100% of control represents activity in the absence of compounds and 0% represents activity determined in the presence of a 40-fold excess of unlabeled HDL or, for Y1-BS1 cells, in the presence of a 1:500 dilution of the KKB-1 blocking antibody (Gu, et al., 2000, generous gift from Karen Kozarsky). The amounts of cell-associated [^{3}H]cholesteryl ether are expressed as the equivalent amount
20   of [^{3}H]CE-HDL protein (ng) to permit direct comparison of the relative amounts of ^{125}I-HDL binding and [^{3}H]CE uptake.

The rates of HDL dissociation from cells were determined by incubation of the cells with ^{125}I-HDL (10 μg protein/ml, 2 hrs, 37°C) with and without BLTs. The medium was then either replaced with the same medium in which the ^{125}I-HDL was substituted by
25   a 40-fold excess of unlabeled HDL or a 40-fold excess of unlabeled HDL was added to the labeled incubation medium. The amounts of cell-associated ^{125}I-HDL were then determined as a function of time. The two methods gave similar results.

(ii) Fluorescence microscopic analysis of intracellular trafficking and cytoskeletal organization.

30   Receptor mediated endocytosis of Alexa-594 labeled transferrin or FITC labeled epidermal growth factor (EGF, Molecular Probes) by HeLa cells (Spiro, et al. (1996) *Mol*

13

Biol Cell **7**, 355-67) and uptake of Alexa-594-labeled holo-cholera toxin (kind gift of Dr

Wayne Lencer, Childrens Hospital, HMS) by BSC-1 cells were detected by fluorescent

microscopy. The intracellular transport of the temperature sensitive glycoprotein of

vesicular stomatitis virus ($VSVG^{ts045}$) fused at its carboxyl terminus to EGFP ($VSVG^{ts045}$-

5   EGFP) from the endoplasmic reticulum to the plasma membrane, after a shift from 40°C

to 32°C for 2hrs, was determined by fluorescent microscopy. The effects of the

compounds on the distribution of actin using rhodamine labeled phalloidin and tubulin

using the FITC labeled DM1 α monoclonal antibody (Sigma Co.) in ldlA[mSR-BI] cells

were determined as described by Rigotti, et al. (1996) *J. Biol. Chem.* **271**, 33545-9 by

10   fluorescence microscopy using an air 63x objective (Nikon).

(iii) Flow cytometric analysis of SR-BI cell surface expression.

        Cells were incubated for 3 hrs (medium C) with or without BLTs at their $IC_{CE}95$

concentrations, harvested with PBS containing 2 mM EDTA and compounds, and the

levels of SR-BI surface expression in unfixed cells were determined by flow cytometry

15   with the KKB-1 antibody (Gu, et al. (1998) *J. Biol. Chem.* **273**, 26338-48).

RESULTS

High-throughput screening for inhibitors of SR-BI-mediated selective lipid uptake.

        Cellular uptake and accumulation of the fluorescent lipophilic dye DiI from DiI-

labeled HDL (DiI-HDL) is a reliable surrogate of SR-BI-dependent selective uptake of

20   the cholesteryl esters in HDL. To identify small molecule inhibitors of SR-BI-mediated

selective lipid uptake, 16,320 compounds representing the DiverSet E of the Chembridge

library collection were screened for their abilities to block the cellular uptake of DiI from

DiI-HDL. The compounds were tested at a nominal concentration of 10 micromolar in a

384-well-plate assay using ldlA[mSR-BI] cells that express a high level of mSR-BI.

25   Figure 1 shows results from a representative assay plate along with controls (no

compounds, addition of excess unlabeled HDL or use of untransfected ldlA-7 cells). The

figure is an example of a fluorescent read-out obtained from a single 384-well plate

during the first round of the high-throughput screen. SR-BI-expressing ldlA[mSR-BI]

cells were plated into 384-well plates and the effect of approximately 10 micromolar

30   compounds on the uptake of DiI from DiI-HDL (10 μg protein/ml) was determined using

a high speed fluorescence plate reader. Columns 1-20 show results (fluorescence in

arbitrary units) from 16 independent wells per column (different colored symbols) from a single plate, representing a total of 320 compounds. Controls without compounds are wells either containing ldlA[mSR-BI] cells in the absence or presence of a 40-fold excess of unlabeled HDL, or containing untransfected ldlA-7 cells (very low SR-BI expression).

5   Wells containing an inhibitory compound named BLT-1 and wells with compounds that quenched DiI-HDL fluorescence (Q) are indicated.

Compounds that quenched ('Q') or enhanced the intrinsic fluorescence of DiI-HDL were not examined further. Approximately 200 compounds that reproducibly blocked DiI uptake in a first round of screening were retested. These are shown in Table

10   I.

Table I: Structures of SR-BI Inhibitors

MIT 9952-1　MIT 9952-2　MIT 9952-3　MIT 9952-4　MIT 9952-5

MIT 9952-6　MIT 9952-7　MIT 9952-8　MIT 9952-9　MIT 9952-10

MIT 9952-11　MIT 9952-12　MIT 9952-13　MIT 9952-14　MIT 9952-15

MIT 9952-16　MIT 9952-17　MIT 9952-18　MIT 9952-19　MIT 9952-20

MIT 9952-21　MIT 9952-22　MIT 9952-23　MIT 9952-24　MIT 9952-25

MIT 9952-26　MIT 9952-27　MIT 9952-28　MIT 9952-29　MIT 9952-30

MIT 9952-31　MIT 9952-32　MIT 9952-33　MIT 9952-34

16

MIT 9952-35

MIT 9952-36

MIT 9952-37

MIT 9952-38

MIT 9952-39

MIT 9952-40

MIT 9952-41

MIT 9952-42

MIT 9952-43

MIT 9952-44

MIT 9952-45

MIT 9952-46

MIT 9952-47

MIT 9952-48

MIT 9952-49

MIT 9952-50

MIT 9952-51

MIT 9952-52

MIT 9952-53

MIT 9952-54

MIT 9952-55

MIT 9952-56

MIT 9952-57

MIT 9952-58

MIT 9952-59

MIT 9952-60

MIT 9952-61

MIT 9952-62

MIT 9952-63

MIT 9952-64

17

MIT 9952-65

MIT 9952-66

$C_{23}H_{24}N_2O$

MIT 9952-67

MIT 9952-68

MIT 9952-69

MIT 9952-70

MIT 9952-71

MIT 9952-72

MIT 9952-73

MIT 9952-74

MIT 9952-75

MIT 9952-76

MIT 9952-77

MIT 9952-78

MIT 9952-79

MIT 9952-80

MIT 9952-81

MIT 9952-82

MIT 9952-83

MIT 9952-84

MIT 9952-85

Na⁺   MIT 9952-86

MIT 9952-87

MIT 9952-88

MIT 9952-89

MIT 9952-90

18

MIT 9952-91

MIT 9952-92

MIT 9952-93

MIT 9952-94

MIT 9952-95

MIT 9952-96

MIT 9952-97

MIT 9952-98

MIT 9952-99

MIT 9952-100

MIT 9952-101

MIT 9952-102

MIT 9952-103

MIT 9952-104

MIT 9952-105

MIT 9952-106

MIT 9952-107

MIT 9952-108

MIT 9952-109

MIT 9952-110

MIT 9952-111

MIT 9952-112

MIT 9952-113

MIT 9952-114

MIT 9952-115

MIT 9952-116

MIT 9952-117

MIT 9952-118

MIT 9952-119

MIT 9952-120

MIT 9952-121

MIT 9952-122

MIT 9952-123

MIT 9952-124

MIT 9952-125

19

MIT 9952-126

MIT 9952-127

MIT 9952-128

MIT 9952-129

MIT 9952-130

MIT 9952-131

MIT 9952-132

MIT 9952-133

MIT 9952-13

MIT 9952-135

MIT 9952-136

MIT 9952-137

MIT 9952-138

MIT 9952-139

MIT 9952-140

MIT 9952-141

MIT 9952-142

MIT 9952-143

MIT 9952-144

MIT 9952-145

MIT 9952-146

MIT 9952-147

MIT 9952-148

MIT 9952-149

MIT 9952-150

MIT 9952-151

MIT 9952-152

MIT 9952-153

MIT 9952-154

MIT 9952-155

MIT 9952-156

MIT 9952-157

MIT 9952-158

MIT 9952-159

MIT 9952-160

MIT 9952-161

MIT 9952-162

MIT 9952-163

MIT 9952-164

MIT 9952-165

MIT 9952-166

MIT 9952-167

MIT 9952-168

MIT 9952-169

MIT 9952-170

MIT 9952-171

MIT 9952-172

MIT 9952-173

MIT 9952-174

MIT 9952-175

MIT 9952-176

MIT 9952-177

MIT 9952-178

MIT 9952-179

MIT 9952-180

MIT 9952-181

MIT 9952-182

MIT 9952-183

MIT 9952-184

MIT 9952-185

MIT 9952-186

MIT 9952-187

MIT 9952-188

MIT 9952-189

MIT 9952-190

MIT 9952-191

MIT 9952-192

MIT 9952-193

MIT 9952-194

MIT 9952-195

MIT 9952-196

MIT 9952-197

MIT 9952-198

MIT 9952-199

MIT 9952-200

MIT 9952-201

MIT 9952-202

MIT 9952-203

MIT 9952-204

MIT 9952-205

MIT 9952-206

MIT 9952-207

MIT 9952-208

MIT 9952-209

MIT 9952-210

MIT 9952-211

MIT 9952-212

MIT 9952-213

MIT 9952-214

MIT 9952-215

MIT 9952-216

MIT 9952-217

MIT 9952-218

MIT 9952-219

MIT 9952-220

MIT 9952-221

MIT 9952-222

MIT 9952-223

MIT 9952-224

MIT 9952-225

MIT 9952-226

MIT 9952-227

MIT 9952-228

MIT 9952-229

MIT 9952-230

MIT 9952-231

22

MIT 9952-232 MIT 9952-233 MIT 9952-234 MIT 9952-235 MIT 9952-236

MIT 9952-237 MIT 9952-238 MIT 9952-239 MIT 9952-240 MIT 9952-241

MIT 9952-242 MIT 9952-243 MIT 9952-244 MIT 9952-245 MIT 9952-246

MIT 9952-247 MIT 9952-248 MIT 9952-249 MIT 9952-250 MIT 9952-251

MIT 9952-252 MIT 9952-253 MIT 9952-254 MIT 9952-255 MIT 9952-256

MIT 9952-257 MIT 9952-258 MIT 9952-259 MIT 9952-260 MIT 9952-261

MIT 9952-262 MIT 9952-263 MIT 9952-264 MIT 9952-265 MIT 9952-266

MIT 9952-267

MIT 9952-268

MIT 9952-269

MIT 9952-270

MIT 9952-271

MIT 9952-272

MIT 9952-273

MIT 9952-274

MIT 9952-275

MIT 9952-276

MIT 9952-277

MIT 9952-278

MIT 9952-279

MIT 9952-280

MIT 9952-281

MIT 9952-282

MIT 9952-283

MIT 9952-284

MIT 9952-285

MIT 9952-286

MIT 9952-287

MIT 9952-288

MIT 9952-289

MIT 9952-290

MIT 9952-291

MIT 9952-292

MIT 9952-293

MIT 9952-294

MIT 9952-295

MIT 9952-296

MIT 9952-297

MIT 9952-298

MIT 9952-299

MIT 9952-300

MIT 9952-301

24

MIT 9952-302

MIT 9952-303

MIT 9952-304

MIT 9952-305

MIT 9952-306

MIT 9952-307

MIT 9952-308

MIT 9952-309

MIT 9952-310

MIT 9952-311

MIT 9952-312

MIT 9952-313

MIT 9952-314

MIT 9952-315

MIT 9952-316

MIT 9952-317

MIT 9952-318

MIT 9952-319

MIT 9952-320

$C_{23}H_{24}N_2O$

MIT 9952-321

MIT 9952-322

MIT 9952-323

MIT 9952-324

MIT 9952-325

MIT 9952-326

MIT 9952-327

MIT 9952-328

MIT 9952-329

MIT 9952-330

MIT 9952-331

25

MIT 9952-332

MIT 9952-333

MIT 9952-334

MIT 9952-335

MIT 9952-336

MIT 9952-337

MIT 9952-338

MIT 9952-339

MIT 9952-340

MIT 9952-341

MIT 9952-342

Five of the most effective compounds with $IC_{DiI}50$s in the micromolar or lower range (Figure 2A) were designated BLT-1-BLT-5 and further characterized. Strikingly, the most potent of these, BLT-1 and BLT-2, inhibited in the nanomolar range and are structurally related (Table II). Inhibition of DiI uptake did not require *de novo* protein synthesis, because pretreatment of cells for 30 min with 100 micrograms/ml cycloheximide did not diminish their inhibitory effects. Finally, none of the BLTs substantially inhibited the low background level of uptake of DiI or [^{3}H]CE by untransfected ldlA-7 cells expressing minimal amounts of SR-BI.

The $IC_{CE}50$s for inhibition of uptake of the more physiologic lipid [^{3}H]cholesteryl ether ([^{3}H]CE) from [^{3}H]CE-HDL by ldlA[mSR-BI] cells were similar to those for DiI uptake (Figure 2B and Table II). The inhibition of [^{3}H]CE uptake was reversible (1 hr incubation with compounds followed by 3-6 hr washout period). Moreover, the compounds also blocked the uptake of [^{3}H]CE by Y1-BS1 adrenocortical cells that express high levels of SR-BI (Rigotti, et al. (1996) *J. Biol. Chem.* 271, 33545-9) (Table II), indicating that the inhibitory effects by the compounds are not cell-type specific. Experiments in which the cells or the labeled HDL were pre-incubated with the compounds indicated that the cells rather than the HDL were the target of the compounds.

TABLE 2:   Results of Testing for SR-BI binding.

Chemical ID	ENDOVIS		ENDOHDL		ENDOQUENCH	
	Test 1	Test 2	Test 1	Test 2	Test 1	Test 2
MIT 9952-1	0		0.62	0.55	1.04	1.14
MIT 9952-2	0		1.34	1.2	1.1	1.06
MIT 9952-3	0		1.32	1.17	1.06	1.2
MIT 9952-4	0		1.17	1.33	1.06	1
MIT 9952-5	0		1.19	1.75	1.02	1.03
MIT 9952-6	0		0.52	0.54	0.99	1.03
MIT 9952-7	0		0.5	0.51	1.02	1.1
MIT 9952-8						
MIT 9952-9	0					

MIT 9952-10					
MIT 9952-11					
MIT 9952-12	0		1.25	1.26	0.9	0.93
MIT 9952-13	0		0.55	0.67	0.94	0.94
MIT 9952-14	0		1.24	1.21	1.16	1.07
MIT 9952-15	0		0.55	0.61	0.87	0.81
MIT 9952-16	0		1.25	1.26	0.92	0.99
MIT 9952-17	0		1.32	1.17	1.06	1.12
MIT 9952-18	0		1.21	1.22	1.01	1.06
MIT 9952-19	0	5				
MIT 9952-20	0	0				
MIT 9952-21	0		1.26	1.58	0.94	0.94
MIT 9952-22	0		1.27	1.4	1.01	1
MIT 9952-23	1	1				
MIT 9952-24	0	0				
MIT 9952-25	0		1.21	1.69	0.98	0.98
MIT 9952-26	0		1.28	1.32	0.95	0.97
MIT 9952-27	0		1.36	1.17	0.9	0.88
MIT 9952-28	7		1.96	1.61	1.0	1.06
MIT 9952-29	0		0.62	0.6	0.94	0.99
MIT 9952-30	0		0.51	0.43	0.91	0.88
MIT 9952-31	0		1.33	1.17	1.01	1.07
MIT 9952-32	0		1.26	1.21	0.9	1.0
MIT 9952-33	0		1.37	1.5	1.04	1.0
MIT 9952-34	0		1.28	1.34	0.94	1.09
MIT 9952-35	0		0.56	0.56	0.99	0.93
MIT 9952-36	0		1.22	1.36	1.02	1.97
MIT 9952-37	0		1.23	1.36	1.03	1.13
MIT 9952-38	0		0.34	0.52	0.17	0.12
MIT 9952-39	0		1.22	1.39	1.08	1.05

MIT 9952-40	0		1.28	1.23	1.01	1.97
MIT 9952-41	0		1.32	1.25	1.06	0.92
MIT 9952-42	0		1.27	1.21	0.97	0.99
MIT 9952-43	0		1.44	1.32	1.09	1.08
MIT 9952-44	0		0.42	0.39	0.86	0.95
MIT 9952-45	0		0.44	0.46	1.35	1.27
MIT 9952-46	0		1.32	1.18	0.99	0.98
MIT 9952-47	0		1.18	1.37	1.14	0.98
MIT 9952-48	0		0.68	0.49	1.13	1.18
MIT 9952-49	0		1.47	1.35	0.95	0.91
MIT 9952-50	0		1.27	1.98	1.02	0.98
MIT 9952-51	0		0.33	0.46	1.02	0.93
MIT 9952-52	0		1.22	1.35	0.92	0.91
MIT 9952-53	0		0.53	0.46	1.0	1.03
MIT 9952-54	6		0.46	0.59	0.95	0.9
MIT 9952-55	0		0.52	0.46	0.98	1.05
MIT 9952-56	0		1.26	1.26	0.91	0.95
MIT 9952-57	0		1.13	1.25	1.05	1.96
MIT 9952-58	0		1.28	1.19	1.02	1.11
MIT 9952-59	0		0.35	0.44	0.86	0.93
MIT 9952-60	0		1.13	1.17	0.89	1.07
MIT 9952-61	0		0.7	0.57	1.09	1.01
MIT 9952-62	0		1.28	1.24	0.99	0.9
MIT 9952-63	0		0.69	0.63	0.95	0.85
MIT 9952-64	0		0.58	0.58	0.98	0.92
MIT 9952-65	0		1.29	1.24	1.07	1.02
MIT 9952-66	0		1.22	1.11	1.96	1.03
MIT 9952-67	0		0.55	0.54	1.24	0.94
MIT 9952-68	0		0.57	0.69	0.84	0.98
MIT 9952-69	0		1.18	1.32	1.07	1.1

MIT 9952-70 (1st)	0		0.45	0.75	0.97	0.88
MIT 9952-71	0		0.62	0.55	1.04	1.14
MIT 9952-72	0	0	1.07	1.12	1.01	0.93
MIT 9952-73	0	0	0.61	0.59	1.02	1.04
MIT 9952-74	0	0	0.71	0.69	0.83	0.88
MIT 9952-75	0	0	0.64	0.71	1.05	1.95
MIT 9952-76	0		1.25	1.26	0.9	0.93
MIT 9952-77	0		0.55	0.67	0.94	0.94
MIT 9952-78	0		1.25	1.26	0.9	0.93
MIT 9952-79	1		0.61	0.63	1.0	0.97
MIT 9952-80	0		1.34	1.2	1.1	1.06
MIT 9952-81	0		1.32	1.17	1.06	1.2
MIT 9952-82	0		1.27	1.4	1.02	1.0
MIT 9952-83	0		1.25	1.26	0.92	0.99
MIT 9952-84	0	0	0.74	0.66	0.83	0.81
MIT 9952-85	0	0	0.56	0.68	1.03	1.12
MIT 9952-86	0		1.24	1.21	1.16	1.07
MIT 9952-87	0	0	0.67	0.67	0.9	0.99
MIT 9952-88	0	0	0.73	0.77	0.92	0.97
MIT 9952-89	0		0.55	0.61	0.87	0.81
MIT 9952-90	0	0	0.62	0.61	1.14	1.02
MIT 9952-91	0	0	0.52	0.54	0.99	1.03
MIT 9952-92	0	0	0.7	0.63	1.11	1
MIT 9952-93	0	0	0.66	0.71	0.95	0.91
MIT 9952-94	0		1.21	1.22	1.01	1.06
MIT 9952-95	2	2	0.79	0.73	0.96	1.03
MIT 9952-96	0		1.32	1.17	1.06	1.2
MIT 9952-97	5	5	0.74	0.69	0.94	0.9
MIT 9952-98	0	5				
MIT 9952-99	0	0				

MIT 9952-100	0		0.5	0.51	1.02	1.1
MIT 9952-101	0	0				
MIT 9952-102	0	0	0.56	0.49	1.05	1.05
MIT 9952-103	1	1	0.56	0.61	0.96	1.09
MIT 9952-104	0	0				
MIT 9952-105	0	0				
MIT 9952-106	0	0	0.6	0.53	1.16	1.16
MIT 9952-107	1	1				
MIT 9952-108	0	0				
MIT 9952-109	0		1.19	1.75	1.02	1.03
MIT 9952-110	0		1.17	1.33	1.06	1.1
MIT 9952-111						
MIT 9952-112	0	0				
MIT 9952-113						
MIT 9952-114	0	0				
MIT 9952-115 (2nd)						
MIT 9952-116	0	0				
MIT 9952-117	0		1.26	1.58	0.94	0.94
MIT 9952-118	0		0.51	0.63	0.91	1.11
MIT 9952-119	0	0	0.62	0.64	1.06	1.04
MIT 9952-120	0		1.21	1.69	0.98	0.98
MIT 9952-121	0	0	0.54	0.57	0.95	1.02
MIT 9952-122	0	0	0.55	0.82	0.82	0.82
MIT 9952-123	0	0	0.59	0.64	1.02	1.05
MIT 9952-124	0		1.33	1.17	1.01	1.17
MIT 9952-125	0	0	0.63	0.66	1.0	0.99
MIT 9952-126	0	0	0.55	0.53	0.93	0.98
MIT 9952-127	0	0	0.62	0.6	0.97	0.92
MIT 9952-128	0		1.23	1.36	1.03	1.13

MIT 9952-129	0	0	0.57	0.54	0.8	0.79
MIT 9952-130	0	0	0.62	0.65	0.96	1.05
MIT 9952-131	0	0	0.56	0.52	0.9	0.92
MIT 9952-132	0	0	0.65	0.46	1.15	1.17
MIT 9952-133	0	0	0.5	0.52	1.15	1.09
MIT 9952-134	0	0	0.58	0.59	0.9	0.9
MIT 9952-135	0	0	0.44	0.46	1.35	1.27
MIT 9952-136	0	0	0.63	0.59	1.12	1.1
MIT 9952-137	0	0	1.32	1.25	1.06	0.92
MIT 9952-138	0	0	0.54	0.63	1.11	1.04
MIT 9952-139	0		1.22	1.39	1.08	1.05
MIT 9952-140	0	0	0.52	0.58	1.44	1.37
MIT 9952-141	0	0	0.63	0.77	1.0	0.99
MIT 9952-142	0		1.28	1.32	0.95	0.97
MIT 9952-143	0	0	0.66	0.65	1.15	1.03
MIT 9952-144	0		0.56	0.56	0.99	0.93
MIT 9952-145	0		1.28	1.34	0.94	1.09
MIT 9952-146	0	0	0.62	0.71	0.95	1.02
MIT 9952-147	0	0	0.63	0.53	0.9	0.99
MIT 9952-148	0		1.44	1.32	1.09	1.08
MIT 9952-149	0	0	0.62	0.6	0.94	0.99
MIT 9952-150	0		0.34	0.52	0.17	0.16
MIT 9952-151(3rd)	0		1.22	1.36	1.02	1.97
MIT 9952-152	0		0.51	0.43	0.91	0.88
MIT 9952-153	0	0	0.6	0.57	0.88	0.91
MIT 9952-154	0	0	0.47	0.45	0.07	0.08
MIT 9952-155	0	0	0.69	0.47	1.04	1.17
MIT 9952-156	0	0	0.57	0.62	1.09	1.03
MIT 9952-157	0	0	1.26	1.21	0.9	1.0
MIT 9952-158	0		0.42	0.39	0.86	0.95

MIT 9952-159	0		1.28	1.23	1.01	0.97
MIT 9952-160	0		0.48	0.55	0.96	1.0
MIT 9952-161	0	0	1.37	1.5	1.04	1.0
MIT 9952-162	0	0	0.55	0.4	1.01	0.95
MIT 9952-163	0	0	0.6	0.69	1.0	1.01
MIT 9952-164	0		0.6	0.61	0.88	0.89
MIT 9952-165	0		0.57	0.6	0.93	0.94
MIT 9952-166	0		0.56	0.67	0.95	0.99
MIT 9952-167	0		1.32	1.18	0.99	0.98
MIT 9952-168	4	4	0.5	0.56	0.93	1.12
MIT 9952-169	0	0	0.54	0.6	1.0	1.04
MIT 9952-170	0	0	0.54	0.54	0.12	0.1
MIT 9952-171	0	0	0.58	0.54	0.96	1.03
MIT 9952-172	0	0	0.55	0.56	0.92	0.84
MIT 9952-173	7		1.96	1.61	1.0	1.06
MIT 9952-174	0	0	0.6	0.62	0.85	0.84
MIT 9952-175	0	0	0.42	0.51	1.0	0.98
MIT 9952-176	0		1.36	1.17	0.9	0.88
MIT 9952-177	0	0	0.68	0.49	1.13	1.18
MIT 9952-178	0	0	0.4	0.38	0.95	0.86
MIT 9952-179	0	0	0.54	0.54	1.08	1.04
MIT 9952-180(4th)	0	0	0.43	0.45	1.14	1.02
MIT 9952-181	0	0	0.6	0.54	1.07	0.95
MIT 9952-182	0	0	0.71	0.41	0.95	1.1
MIT 9952-183	0	0	0.59	0.65	0.94	1.0
MIT 9952-184	0	0	0.6	0.58	0.93	0.94
MIT 9952-185	0	0	0.53	0.46	1.0	1.03
MIT 9952-186	0	0	0.5	0.5	1.07	1.05
MIT 9952-187	0		0.33	0.46	1.02	0.93
MIT 9952-188	0	0	0.61	0.58	0.94	1.08

MIT 9952-189	0	0	0.56	0.58	1.09	1.0
MIT 9952-190	0		1.47	1.35	0.95	0.91
MIT 9952-191	0		1.27	1.98	1.02	0.98
MIT 9952-192	0	0	0.57	0.52	1.1	1.09
MIT 9952-193	0	0	0.66	0.69	0.92	1.0
MIT 9952-194	0	0	0.76	0.46	0.97	1.02
MIT 9952-195	0		1.22	1.35	0.92	0.91
MIT 9952-196	0	0	0.63	0.6	1.09	1.07
MIT 9952-197	0	0	0.58	0.71	0.95	0.96
MIT 9952-198	0	0	0.67	0.64	1.07	1.11
MIT 9952-199	0	0	0.52	0.46	0.98	1.05
MIT 9952-200	0	0	0.73	0.8	1.02	0.96
MIT 9952-201	0	0	0.69	0.67	1.26	1.25
MIT 9952-202	0	0	1.23	1.11	0.98	1.03
MIT 9952-203	0	0	0.73	0.7	0.97	1.0
MIT 9952-204	0	0	0.55	0.62	0.78	1.07
MIT 9952-205	0	0	1.08	1.0	0.93	1.03
MIT 9952-206	0	0	0.56	0.52	1.05	1.1
MIT 9952-207	0		1.28	1.19	1.02	1.11
MIT 9952-208	0	0	0.57	0.55	0.95	0.98
MIT 9952-209 (5th)	6		0.46	0.59	0.95	0.9
MIT 9952-210	0	0	0.59	0.56	0.88	0.91
MIT 9952-211	0	0	0.59	0.56	1.02	1.07
MIT 9952-212	0	0	0.57	0.49	1.0	0.95
MIT 9952-213	0	0	0.66	0.57	0.92	0.96
MIT 9952-214	0	0	0.63	0.35	1.05	1.0
MIT 9952-215	0	0	0.57	0.53	1.03	1.04
MIT 9952-216	0	0	0.54	0.58	1.1	1.14
MIT 9952-217	0	0	0.57	0.53	1.0	0.98

MIT 9952-218	0	0	0.64	0.33	1.06	1.0
MIT 9952-219	0	0	0.55	0.55	0.95	0.98
MIT 9952-220	0	0	1.13	1.25	1.05	0.96
MIT 9952-221	0	0	0.62	0.59	1.01	0.91
MIT 9952-222	4	4	0.58	0.6	1.07	0.9
MIT 9952-223	0	0	0.64	0.57	1.06	1.05
MIT 9952-224	0	0	0.6	0.5	0.99	0.97
MIT 9952-225	0	0	0.56	0.59	1.05	1.03
MIT 9952-226	0	0	0.5	0.56	0.95	1.0
MIT 9952-227	0	0	0.58	0.53	0.96	1.0
MIT 9952-228	0	0	0.46	0.63	0.93	0.94
MIT 9952-229	0	0	0.58	0.58	1.22	1.31
MIT 9952-230	2	2	0.61	0.51	0.99	1.01
MIT 9952-231	0	0	0.46	0.54	0.99	0.96
MIT 9952-232	0	0	0.61	0.56	0.99	1.02
MIT 9952-233	0	0	0.59	0.33	1.0	0.94
MIT 9952-234	0	0	0.58	0.54	0.94	0.93
MIT 9952-235	0	0	0.62	0.33	0.91	1.06
MIT 9952-236	0	0	0.57	0.38	0.97	1.23
MIT 9952-237	0	0	0.53	0.39	0.91	0.83
MIT 9952-238	0	0	0.61	0.6	1.01	1.13
MIT 9952-239 (6th)	0	0	0.48	0.4	0.9	0.96
MIT 9952-240	0	0	0.64	0.71	0.97	1.07
MIT 9952-241	1	1	0.48	0.52	0.92	0.93
MIT 9952-242	0		1.26	1.26	0.91	0.95
MIT 9952-243	0	0	0.42	0.6	1.05	1.09
MIT 9952-244	0	0	0.56	0.54	1.02	1.07
MIT 9952-245	0	0	0.54	0.64	1.03	1.02
MIT 9952-246	0	0	0.56	0.52	0.99	0.98

MIT 9952-247	0	0	0.63	0.64	1.05	1.03
MIT 9952-248	0	0	0.68	0.66	0.98	0.91
MIT 9952-249	0	0	0.7	0.57	1.09	1.01
MIT 9952-250	0	0	1.28	1.24	0.99	0.9
MIT 9952-251	0	0	0.52	0.57	1.06	1.06
MIT 9952-252	1	1	0.58	0.39	0.98	0.9
MIT 9952-253	0	0	0.59	0.65	1.03	1.06
MIT 9952-254			0.69	1.01	0.91	1.05
MIT 9952-255	0	0	0.61	0.6	1.01	0.94
MIT 9952-256	0	0	0.65	0.92	0.92	0.97
MIT 9952-257	0	0	0.66	0.61	1.0	1.0
MIT 9952-258	0	0	0.51	1.0	0.88	0.82
MIT 9952-259	0	0	0.59	0.55	0.96	0.94
MIT 9952-260	0	0	0.56	0.58	1.06	1.04
MIT 9952-261	0	0	0.62	0.66	1.05	1.05
MIT 9952-262	0	0	0.53	0.45	0.98	1.01
MIT 9952-263	0	0	0.66	0.65	1.04	0.98
MIT 9952-264	0	0	0.45	0.56	1.1	1.11
MIT 9952-265	0	0	0.26	0.89	0.8	0.87
MIT 9952-266	0	0	0.71	0.68	1.08	1.01
MIT 9952-267	0	0	0.57	1.11	0.96	1.07
MIT 9952-268 (7th)	0	0	0.59	0.65	0.98	1.04
MIT 9952-269	0	0	0.74	0.66	0.99	1.05
MIT 9952-270	0	0	0.66	0.66	0.95	0.96
MIT 9952-271	0	0	0.59	0.54	0.94	0.89
MIT 9952-272	0	0	0.61	0.51	0.91	0.92
MIT 9952-273	0	0	0.51	0.48	0.79	0.73
MIT 9952-274	0	0	0.65	0.6	0.93	0.93
MIT 9952-275	0	0	0.43	0.44	0.92	0.97

MIT 9952-276	0	0	0.73	0.68	1.03	1.0
MIT 9952-277	0	0	0.66	0.65	1.0	1.0
MIT 9952-278	0	0	0.71	0.67	1.09	0.98
MIT 9952-279	0	0	0.64	0.63	1.12	1.11
MIT 9952-280	0	0	0.75	0.67	1.01	1.12
MIT 9952-281	0	0	0.59	0.34	1.0	0.96
MIT 9952-282	0	0	0.49	0.5	0.82	0.89
MIT 9952-283	0	0	0.53	0.48	0.97	1.0
MIT 9952-284	0	0	0.65	0.54	0.91	0.96
MIT 9952-285	0	0	0.57	0.53	0.9	1.07
MIT 9952-286	0	0	0.62	0.64	0.96	1.11
MIT 9952-287	0		1.18	1.32	1.07	1.1
MIT 9952-288	0	0	0.59	0.52	0.77	0.77
MIT 9952-289	0	0	0.6	0.64	1.0	0.98
MIT 9952-290	0	0	0.52	0.56	0.87	0.82
MIT 9952-291	0	0	0.55	0.51	0.94	0.97
MIT 9952-292	0	0	0.47	0.58	1.06	1.01
MIT 9952-293	0	0	0.69	0.67	0.85	0.95
MIT 9952-294	0	0	0.61	0.56	0.93	0.95
MIT 9952-295	0	0	0.64	0.58	1.01	0.95
MIT 9952-296	0	0	0.63	0.61	1.05	0.98
MIT 9952-297	0	0	0.56	0.46	1.07	1.09
MIT 9952-298 (8th)	0	0	1.29	1.24	1.07	1.02
MIT 9952-299	0		0.73	0.57	1.05	0.99
MIT 9952-300	0		0.66	0.66	1.18	0.97
MIT 9952-301	0		0.71	0.7	1.01	0.98
MIT 9952-302	0	0	0.52	0.55	0.79	0.85
MIT 9952-303	0		0.58	0.58	0.98	0.92
MIT 9952-304	0		0.35	0.44	0.86	0.93

MIT 9952-305	0	0	0.67	0.6	1.07	1.01
MIT 9952-306	0		0.79	0.72	1.0	0.96
MIT 9952-307	0		0.69	0.63	0.95	0.85
MIT 9952-308	0		0.57	0.69	0.84	0.98
MIT 9952-309	0		0.7	0.68	1.14	1.08
MIT 9952-310	0		0.97	1.11	0.96	1.01
MIT 9952-311	0		0.63	0.65	0.98	0.99
MIT 9952-312	0		0.45	0.75	0.97	0.88
MIT 9952-313	0		0.79	0.77	0.94	0.98
MIT 9952-314	0		0.55	0.54	1.24	0.94
MIT 9952-315	0	0	0.51	0.53	0.86	0.73
MIT 9952-316	0		0.71	0.72	1.13	1.1
MIT 9952-317	0		0.69	0.73	1.0	0.96
MIT 9952-318	0		0.67	0.81	1.18	0.94
MIT 9952-319	0		1.13	1.17	0.89	1.07
MIT 9952-320	0		0.54	0.83	1.04	1.01
MIT 9952-321	0		1.22	1.11	1.96	1.03
MIT 9952-322	0	°	0.79	0.86	0.1	0.96
MIT 9952-323	0	0	0.46	0.63	0.93	0.94
MIT 9952-324	0	0	0.55	0.56	0.92	0.84
MIT 9952-325	0	0	0.56	0.49	1.05	1.05
MIT 9952-326	0	0	0.55	0.53	0.93	0.98
MIT 9952-327	0	0	0.4	0.45	1.18	1.13
MIT 9952-328	4	4	0.5	0.56	0.93	1.12
MIT 9952-329	0	0	0.57	0.53	1.0	0.98
MIT 9952-330	0	0	0.59	0.56	1.02	1.07
MIT 9952-331	0	0	0.63	0.35	1.05	1.0
MIT 9952-332	0	0	0.69	0.67	1.26	1.25
MIT 9952-333	0	0	0.56	0.59	1.05	1.03
MIT 9952-334	0	0	0.57	0.55	0.95	0.98

MIT 9952-335	0	0	0.57	0.49	1.0	0.95
MIT 9952-336	0	0	0.54	0.58	1.1	1.14
MIT 9952-337	0	0	0.6	0.57	0.92	0.96
MIT 9952-338 (9th)	0	0	0.61	0.6	1.01	1.13
MIT 9952-339	0	0	0.58	0.54	0.94	0.93
MIT 9952-340	0	0	0.48	0.44	0.9	0.96
MIT 9952-341	2	2	0.61	0.51	0.99	1.01
MIT 9952-342	0	0	0.43	0.44	0.92	0.97

Inhibition of selective lipid uptake by BLTs is specific.

The specificity of BLT inhibition was tested by testing their effects on several other cellular properties at their concentrations that inhibit [^{3}H]CE uptake by 95% (IC$_{CE}$95) (Fig 3). None of the BLTs disrupted the integrity of the actin- and tubulin networks. They also did not inhibit the uptake or alter the intracellular distribution of the fluorescently labeled endocytic receptor ligands transferrin and epidermal growth factor. The BLTs also failed to inhibit the uptake of fluorescently labeled cholera toxin from the cell surface to perinuclear regions through a pathway believed to depend in part on cholesterol- and sphingolipid-rich lipid rafts (Lencer, et al. (1999) *Biochim. Biophys. Acta* **1450**, 177-190). Moreover, BLTs did not interfere with the secretory pathway, as assessed by analysis of the transport of the enhanced green fluorescent protein-labeled integral viral membrane glycoprotein VSV G (VSVG^{ts045}-EGFP). Thus, BLTs do not induce general defects in clathrin-dependent and clathrin-independent intracellular membrane trafficking or in the organization of the cytoskeleton and are, by these criteria, specific inhibitors of SR-BI-dependent lipid uptake.

BLTs inhibit SR-BI-mediated cholesterol efflux from cells to HDL.

In addition to mediating selective lipid uptake from HDL, SR-BI can facilitate the efflux of unesterified cholesterol from cells to HDL particles (Jian, et al. (1998) *J Biol Chem* **273**, 5599-606.Ji, et al. (1997) *J. Biol. Chem.* **272**, 20982-5). To determine if the BLTs could inhibit this SR-BI-mediated lipid transport activity, cells were labeled with

[^{3}H]cholesterol and its efflux to unlabeled HDL measured in the presence or absence of the BLTs. (Figure 2C, table II). Cells were incubated for 3 hrs in the absence (top panels) or presence (bottom panels) of 50 micromolar BLT-1 (MIT 9952-53) and epifluorescence light microscopy was used to monitor the following cellular activities: clathrin-dependent endocytosis of fluorescently labeled transferrin (A,B; HeLa cells) and EGF (C,D; HeLa cells); clathrin-independent endocytosis of fluorescently labeled cholera toxin (E, F; BSC-1 cells), and transport of the temperature sensitive fluorescent membrane protein VSVG^{ts045}-EGFP from the ER to the cell surface (G,H; BSC-1 cells). In addition, the intracellular distributions of the actin cytoskeleton (visualized with rhodamine labeled phalloidin, I,J; ldlA-[mSRBI] cells) and the tubulin network (visualized with fluorescently labeled antibodies specific to γ-tubulin, K,L; BSC-1 cells) were determined. BLT-1 (MIT 9952-53) and the other BLTs (not shown) had no effects on any of these cellular properties or activities.

As shown in Table III, all BLTs inhibited SR-BI-mediated cholesterol efflux with relative potencies (IC$_{FC}$50s) similar to those for [^{3}H]CE uptake; although in the cases of BLT-3 (MIT 9952-19), BLT-4 (MIT 9952-29) and BLT-5 (MIT 9952-6), the IC$_{FC}$50s for efflux were higher than those for uptake, suggesting that the BLTs may have uncovered possible differences in the mechanisms of uptake and efflux. The BLTs had little effect on the SR-BI-independent efflux (not inhibited by the specific anti-SR-BI blocking antibody KKB-1) (Kapoor, et al. (2000) *Journal of Cell Biology* **150**, 975-88). In untransfected ldlA-7 cells expressing relatively low levels of endogenous SR-BI, total and SR-BI-dependent (e.g. KKB-1-inhibitable) cholesterol efflux were substantially lower (~5-10-fold) than in ldlA[mSR-BI] cells. The BLTs were able to inhibit the low SR-BI-dependent cholesterol efflux in ldlA-7 cells, but had no inhibitory effect on the similarly low SR-BI-independent efflux.

TABLE III

	n	BLT-1 mean ± SD	BLT-2 mean ± SD	BLT-3 mean ± SD	BLT-4 mean ± SD	BLT-5 mean ± SD	No BLT mean ± SD
(A) EC50 (μM)							
DiI-HDL uptake	3	0.06 ± 0.04	0.35 ± 0.18	0.51 ± 0.15	2.0 ± 1.0	7.1 ± 3.7	- -
[^{3}H]CEt HDL uptake	6	0.11 ± 0.08	0.24 ± 0.1	2.3 ± 1.5	3.9' ± 0.76	13.8' ± 8.5	- -
(Y1-BS1 cells)	2	0.38 NA	0.41 NA	1.7 NA	4.4 NA	8.0 NA	-
[^{3}H]cholesterol efflux	3	0.15 ± 0.09	0.47 ± 0.23	17.2 ± 4.0	54.9 ± 35.2	75.3 ± 40.1	- -
^{125}I-HDL binding	3	0.088 ± 0.05	0.25 ± 0.13	46.5 ± 49.3	24.9 ± 14.8	18.0 ± 3.7	- -
(B) Binding Parameters							
apparent K_d (μg ml^{-1})	3	4.7 ± 0.05	6.0 ± 6.0	8.0 ± 4.0	8.9 ± 2.3	12.0 ± 1.6	16.6 ± 1.5
K_{eff} (min^{-1})	2	0.06 NA	0.062 NA	0.08 NA	0.082 NA	0.079 NA	0.11 NA
Bmax (%)		95.8 ± 10.1	93.0 ±20.5	85.8 ± 15.8	79.9 ± 15.9	92.1 ± 36.8	100.0 ± 18.4
EC_{50} (μM)							

'n=5

Footnote: all experiments were with ldlA [mSR-BI] cells except where noted.

41

BLTs do not change the surface expression of SR-BI.

To determine if BLTs inhibited SR-BI function by reducing its cell surface expression, we measured surface expression using the KKB-1 anti-mSR-BI antibody and flow cytometry. Figure 4 shows that, after a 3 hr incubation at their $IC_{CE}95s$ (corresponding to1 μM for BLTs 1 (MIT 9952-53) and 2 (MIT 9952-61), 50 μM for BLTs 3-5 (MIT 9952-19, MIT 9952-29, and MIT 9952-6)), the BLTs did not alter the expression of mSR-BI on the surfaces of ldlA[mSR-BI] cells.

BLTs enhance binding of HDL to SR-BI.

It was initially expected that the BLTs would function by inhibiting HDL binding to SR-BI. However, when cells were incubated with a sub-saturating concentration of either [^{3}H]CE-HDL or ^{125}I-labeled HDL (^{125}I-HDL) (10 μg protein/ml) and increasing amounts of compound (Figure 5), the *decreases* in [^{3}H]CE uptake (solid lines, no symbols, data from Figure 2B) and [3H]cholesterol efflux (dashed lines, data from Figure 2C) were accompanied by corresponding *increases* in ^{125}I-HDL binding (solid lines, square symbols). The concentration dependence of ^{125}I-HDL binding was determined in the presence or absence of BLTs at their $IC_{CE}95$ concentrations (Figure 6 and Table II). The BLTs did not substantially alter the number of binding sites (B_{max}), but rather induced small, yet significant, increases in the affinity of SR-BI for HDL (lower apparent Kds). Furthermore, the BLTs reduced the rates of dissociation of ^{125}I-HDL from SR-BI (Table II), indicating that the tighter binding induced by the BLTs was due, at least in part, to a decrease in the dissociation rate.

DISCUSSION

200 compounds, shown in Table I, altering SR-BI mediated lipid transport were identified using *in vitro* assays. Results of testing are shown in Table II. BLT-1 (MIT 9952-53) through BLT-5 (MIT 9952-6) were identified as small molecules that inhibit the transfer of lipids between HDL and cells mediated by the HDL receptor SR-BI. BLTs inhibited both cellular selective lipid uptake of HDL cholesteryl ether and efflux of cellular cholesterol to HDL. The inhibitory effects of the BLTs were specific (for example, they specifically alter SR-BI binding), as they required the expression of active SR-BI receptors and they did not interfere with several clathrin-dependent and

independent endocytic pathways, the secretory pathway nor the actin- or tubulin cytoskeletal networks. Strikingly, inhibition of lipid transfer by BLTs was accompanied by enhanced HDL binding affinity (reduced dissociation rates).

Modifications and variations of the methods and materials described herein will be obvious to those skilled in the art and are intended to be encompassed by the following claims. The teachings of the references cited herein are specifically incorporated herein.